A study of visual hallucinations in patients with Parkinson's disease

Journal of Neurology

Volumn 244, Issue 6, 1997, Pages 371-377

  Klein, Christine ^a   Kömpf, Detlef ^a   Pulkowski, Ulrich ^a   Moser, Andreas ^a   Vieregge, Peter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Aging; Dementia; Hallucinations; Parkinson's disease; Psychosis

Indexed keywords

SELEGILINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMENTIA; DISABILITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH; NURSING HOME; PARKINSON DISEASE; PRIORITY JOURNAL; SLEEP DISORDER; VISUAL HALLUCINATION;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; VISUAL PERCEPTION;

EID: 0030837785     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150050104     Document Type: Article

References (50)

1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM III), 3rd edn, revised. American Psychiatric Press, Washington DC
2. Auzou P, Özsancak C, Mannequin D, Morre N, Augustin P (1996) Clozapine for the treatment of psychosis in Parkinson's disease: a review. Acta Neurol Scand 94:329-336
3. Bayles KA, Tomoeda CK, Wood JA, Montgomery EB Jr, Cruz RF, Azuma T, McGeagh A (1996) Change in cognitive function in idiopathic Parkinson disease. Arch Neurol 53:1140-1146
4. Claus D, Aschoff JC (1982) Evaluation of infratentorial atrophy by computed tomography. J Neurol Neurosurg Psychiatry 45:979-983
5. Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 34:710-714
6. De Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 45:1161-1164
7. Diederich N, Keipes M, Graas M, Metz H (1995) La clozapine dans le traitement des manifestations psychiatriques de la maladie de Parkinson. Rev Neurol (Paris) 151:251-257
8. Dubois B, Pillon B (1996) Cognitive deficits in Parkinson's disease. J Neurol 244:2-8
9. Fahn S, Elton RS, members of the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease, vol II. Macmillan, Florham Park, NJ, pp 153-163
10. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 2:189-198
11. Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51:745-752
12. Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43:2227-2229
13. Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45:669-671
14. Goetz CG, Tanner CM, Klawans HL (1982) Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 139:494-497
15. Hahn FJY, Rim K (1976) Frontal ventricular dimensions on normal computed tomography. AJR 126:593-596
16. Harper RW, Knothe BUC (1973) Coloured lilliputian hallucinations with amantadine. Med J Austr 1:444-445
17. Haug G (1977) Age and sex dependence of the size of normal ventricles on computed tomography. Neuroradiology 14:201-204
18. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427-142
19. Jacoby RJ, Levy R, Dawson JM (1980) Computed tomography in the elderly. 1. The normal population. Br J Psychiatry 136:249-255
20. Kahn N, Freeman A, Juncos JL, Manning D, Watts RL (1991) Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 41:1699-1700
21. Klatka LA, Louis ED, Schiffer RB (1996) Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology 47:1148-1152
22. Kömpf D (1993) Visuelle Halluzinationen - neurologische Aspekte. Nervenarzt 64:360-368
23. Kosaka K (1990) Diffuse Lewy body disease in Japan. J Neurol 237:197-204
24. Le May M (1984) Radiologic changes of the aging brain and skull. AJR 143:383-389
25. Masdeu JC, Wolfson L, Lantos G, Tobin JN, Grober E, Whipple R, Amerman P (1989) Brain white-matter changes in the elderly prone to falling. Arch Neurol 46:1292-1296
26. McKeith IG, Fairbairn AF, Bothwell RA Moore PB, Ferrier IN, Thompson P, Perry RH (1994) An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 44:872-877
27. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, Vos RAI de, Wilcock GK, Jellinger KA, Perry RH for the consortium on dementia with Lewy bodies (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113-1124
28. Meco G, Bonifati V, Cusimano G, Fabrizio E, Vanacore N (1990) Hallucinations in Parkinson's disease: neuropsychological study. Ital J Neurol Sci 11:373-379
29. Moser A, Siebecker F, Vieregge P, Jaskowski P, Kömpf D (1996) Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. J Neural Transm 103:421-432
30. Moskovitz C, Moses H, Klawans HL (1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135:669-675
31. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL (1982) Sleep disruption in the course of chronic levodopa therapy: an early feature of levodopa psychosis. Clin Neuropharmacol 5:183-194
32. Pahwa R, Lyons K, Hubble J, Paolo T, Karst A, Villagra F, Glatt S, Koller WC (1995) Hallucinations in Parkinson's disease patients correlate with cognitive impairment. Mov Disord 10:695
33. Pederzoli M, Girotti F, Scigliano G, Aiello G, Carella F, Caraceni T (1983) L-dopa long-term treatment in Parkinson's disease: age-related side effects. Neurology 33:1518-1522
34. Perry EK, Perry RH (1995) Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 28:240-258
35. Perry R, Irving D, Blessed G, Fairburn A, Perry EK (1995) Senile dementia of the Lewy body type. J Neurol Sci 95: 119-139
36. Sanchez-Ramos JR, Ortoll R, Paulson GW (1996) Visual hallucinations associated with Parkinson's disease. Arch Neurol 53:1265-1268
37. Schneider E, Fischer P-A, Jacobi P, Becker H, Beyer M (1979) Cerebral atrophy and long-term response to levodopa in Parkinson's disease. J Neurol 222:37-43
38. Schwab RS, England AC Jr (1969) Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML (eds) Third symposium on Parkinson's disease. Livingstone, Edinburgh, pp 152-157
39. Serby M, Angrist B, Lieberman A (1978) Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease. Am J Psychiatry 135:1227-1229
40. Sokal RR, Rohlf FJ (1969) Biometry. Freeman, San Francisco
41. Sweet RD, McDowell FH, Feigenson JS, Loranger AW, Goodell H (1976) Mental symptoms in Parkinson's disease during chronic treatment with levodopa. Neurology 26:305-310
42. Tanner CM, Vogel C, Goetz CG, Klawans HL (1983) Hallucinations in Parkinson's disease: a population study. Ann Neurol 14:136
43. Swieten JC van, Hijdra A, Koudstaal PJ, Gijn J van (1990) Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry 53:1080-1083
44. Verhoeven WMA, Tuinier S (1994) Dopaminometic psychosis: thoughts on etiology. In: Wolters EC, Scheltens P (eds) Mental dysfunction in Parkinson's disease. ICG, The Netherlands, pp 267-280
45. Vieregge P, Dethlefsen J (1992) Krankengymnastik und Logopädie beim Parkinson-Syndrom - eine Bestandsaufnahme. Fortschr Neurol Psychiatr 60:369-374
46. Vieregge P, Fassl H, Kleinhenz J, Kuhnholdt U, Jörg J (1991) Ambulante Betreuung von Patienten mit Parkinsonismus - eine Pilotstudie. Ger Forsch 1:15-25
47. Vieregge P, Körtke D, Meyer-Bornsen K (1994) Ärztliche Betreuung und soziale Situation älterer Parkinson-Patienten. Z Gerontol 27:260-269
48. Vieregge P, Verleger R, Wascher E, Stüven F, Kömpf D (1994) Auditory selective attention is impaired in Parkinson's disease. Cogn Brain Res 2:117-129
49. Webster DD (1968) Critical analysis of the disability in Parkinson's disease. Mod Treat 5:257-282
50. Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM (1996) Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 47:1085-1087